Status:
COMPLETED
DOTA-TOC in Metastasized Neuroendocrine Tumors
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The investigators aim to explore the efficacy of \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC therapy in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and long-term ...
Detailed Description
Background: Systemic treatment with the 90Yttrium (90Y) labeled, tetraazacyclododecanetetraacetic acid (DOTA) modified somatostatin analog Tyr3-octreotide (TOC) was introduced in 1998 (Otte et al. Lan...
Eligibility Criteria
Inclusion
- histologically confirmed neuroendocrine cancer
- stage IVc disease by definition of the American Joint Committee on Cancer, i.e. occurrence of distant metastases
- visible tumor uptake in the pretherapeutic somatostatin receptor subtype 2 scintigraphy (111In-Octreoscan)
Exclusion
- concurrent anti-tumor treatment
- secondary malignancies
- pregnancy
- breast-feeding
- incontinence
- severe concomitant illness including severe psychiatric disorders
Key Trial Info
Start Date :
September 1 1997
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
1499 Patients enrolled
Trial Details
Trial ID
NCT00978211
Start Date
September 1 1997
End Date
December 1 2013
Last Update
August 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Basel, Canton of Basel-City, Switzerland, 4031